Posts by: Alice Melão

News

A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma patients with stable disease in ... Read more

December 10, 2018

AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma

News

Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least two prior lines of therapy. The ... Read more

December 3, 2018

Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients

News

Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study the safety and tolerability of its investigational antibody SEA-BCMA. The ... Read more

November 7, 2018November 26, 2018

Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows

News

Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or death in newly diagnosed multiple myeloma patients who are not eligible for high-dose chemotherapy and ... Read more

October 19, 2018

Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as a treatment for multiple myeloma patients ... Read more

October 17, 2018

Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals

News

Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience Survey reveals. The figure is much ... Read more

October 15, 2018

FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia

News

The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the small number of cancer cells that ... Read more

September 24, 2018

Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma

News

SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the treatment of multiple myeloma patients, according to a press release. ... Read more

July 27, 2018

Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients

News

Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma patients. The company has begun the ... Read more

July 11, 2018

Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US

News

Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study shows. The findings highlight ... Read more

Posts by: Alice Melão

Alice Melão

Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial

AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients

Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows

Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma

Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals

FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia

Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma

Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients

Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US

Pin It on Pinterest